DECAPRYN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Decapryn, and what generic alternatives are available?
Decapryn is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in DECAPRYN is doxylamine succinate. There are fourteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the doxylamine succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Decapryn
A generic version of DECAPRYN was approved as doxylamine succinate by PERRIGO on September 18th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DECAPRYN?
- What are the global sales for DECAPRYN?
- What is Average Wholesale Price for DECAPRYN?
Summary for DECAPRYN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 95 |
| Patent Applications: | 1,394 |
| DailyMed Link: | DECAPRYN at DailyMed |
US Patents and Regulatory Information for DECAPRYN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | DECAPRYN | doxylamine succinate | TABLET;ORAL | 006412-015 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | DECAPRYN | doxylamine succinate | TABLET;ORAL | 006412-014 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
